Column – December 20, 2024
As this year’s Nobel Prize winners were walking into Stockholm City Hall for festivities recently, the temperature was climbing below zero in the December night outside.
Denmark – December 18, 2024
Novo Nordisk has announced plans to establish a completely new production facility in Odense, Denmark.
Acquisition – December 18, 2024
Ultimovacs and Zelluna Immunotherapy have announced that Ultimovacs and shareholders of Zelluna representing more than 99% of the total number of issued and outstanding shares in Zelluna have entered into a definitive business combination agreement to combine the two companies in a share exchange transaction.
Clinical Trials – December 18, 2024
Hansa Biopharma has announced positive full results from the 15-HMedIdeS-09 single arm Phase 2 study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome (GBS) and an indirect treatment comparison of the 15-HMedIdeS-09 study data to the International Guillain-Barré Syndrome Outcome Study (IGOS), a worldwide prospective study by the Inflammatory Neuropathy Consortium on prognosis and biomarkers of GBS.
Financing – December 18, 2024
The PrimaryBid Offering attracted strong interest from both new and existing investors, with participation from over 200 retail investors across Norway, Denmark and Finland.
Intellectual Property – December 18, 2024
Orexo has recently entered a settlement agreement with Sun Pharmaceuticals Industries to resolve a patent litigation regarding the company’s Zubsolv sublingual tablet for the treatment of opioid use disorder in the US. NLS asked Nikolaj Sørensen, CEO of Orexo, about the impact of this settlement and his thoughts on the patent litigation process and generic challenges.
Clinical Trials – December 18, 2024
Hansa Biopharma has announced positive full results from the 15-HMedIdeS-09 single arm Phase 2 study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome (GBS) and an indirect treatment comparison of the 15-HMedIdeS-09 study data to the International Guillain-Barré Syndrome Outcome Study (IGOS), a worldwide prospective study by the Inflammatory Neuropathy Consortium on prognosis and biomarkers of GBS.
Clinical Trials – December 11, 2024
Immunovia has announced the successful completion of the CLARITI study, (Clinical Validation of Next-Generation Test for Early-Stage Pancreatic Cancer) to detect early-stage pancreatic ductal adenocarcinoma (PDAC).
Clinical Trials – December 10, 2024
The first dose has been administered in the company’s Phase II clinical study evaluating the drug candidate sevuparin for the treatment of chronic kidney disease (CKD) with associated anemia.
Clinical Trials – December 3, 2024
The trial will be conducted in patients with pre-existing anti-AAV antibodies which limit use of gene therapy treatment.
Clinical Trials – November 19, 2024
Modus Therapeutics has received approval from the relevant authorities in Italy for its planned Phase IIa clinical trial with sevuparin.
Clinical Trials – November 19, 2024
Alligator Bioscience and Aptevo Therapeutics report favorable safety, tolerability and evidence of biological activity of ALG.APV-527, with more than half of evaluable patients achieved stable disease.
Biotech Business – December 16, 2024
Medivir has announced the approval of the US Investigational New Drug application (IND) for evaluating fostrox + Lenvima vs Lenvima alone in a phase 2b study in 2nd line advanced HCC.
Agreement – December 2, 2024
The two companies have decided to terminate the partnership agreement, covering the rights for Orexo to commercialize the digital mental health program for depression, Deprexis, in the US.
Biotech Business – November 20, 2024
Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for Xbrane´s Nivolumab Biosimilar candidate (referencing Opdivo).
Collaboration – December 3, 2024
Capitainer plays a key role in the international AIR project (Artificial Intelligence Radiology) aimed at improving the diagnostics and monitoring of lung diseases.
Intellectual Property – December 2, 2024
The company has been granted a US patent for its SiPore platform technology.
MedTech Business – November 13, 2024
Capitainer has announced the establishment of Capitainer Inc. in the United States. This expansion will enhance customer service and streamline order processing for the company’s growing US market, further strengthening Capitainer’s goal to become the gold standard and global leader in self-sampling, the company states.
Biotech Business – December 17, 2024
Orexo has entered into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology.
Biotech Business – December 13, 2024
The company is preparing to launch a phase II clinical trial in pancreatic cancer with funds from a recent private placement.
Biotech Business – December 10, 2024
The European Medicines Agency (EMA) has granted Advanced Therapy Medicinal Product (ATMP) classification to NEOGAP’s cell therapy, pTTL (personalized Tumor Trained Lymphocytes).
Science – July 8, 2024
Unfortunately genes do matter when it comes to obesity, but knowledge about these genes and how they work are key to improving treatment and prevention.
Profiles in Science – June 18, 2024
Anna Falk, Head of Lund University’s Center for Advanced Therapies (LU-ATMP) and principal researcher of the Department of Neuroscience at Karolinska Institutet (KI) shares insights into her research, her multi-faceted job, and her vision for the future of neuroscience. Anna Falk is a molecular biologist with a PhD in neural stem cells and adult neurogenesis. […]
Science – September 20, 2023
An international team of scientists led by the University of Helsinki performed comprehensive mapping of structural alterations in cellular proteins during the aging process. In the study published in Molecular Cell, the team mapped structural alterations in cellular proteins during the aging process and, in the process, identifying new ways aging impacts how cells hum […]
ArgusEye
An opportunity to use your strategic mindset and sales expertise to make a transformative impact in the biopharmaceutical industry.
Stryker
In this role, you will help us deliver on our mission of making healthcare better by promoting and selling Stryker’s world-class Neurovascular product portfolio. You will cover the Swedish territory.
Diamyd Medical
If you are an experienced Cultivation Specialist/Scientist and are looking for a new position at a company with an exciting future ahead this might be something for you.
Diamyd Medical
Do you have experience with submission of Biologics License Application?
MEQU
The Company °MEQU a Danish MedTech Start-up company placed in Copenhagen, manufactures the most effective portable blood and IV fluid warmer for use in emergency medical services and hospitals. °MEQU was founded in 2011 by Ulrik Krogh Andersen. The °M Warmer System was developed following a request from the Danish military to the Danish Technology […]
BÜCHI Labortechnik
The Company BÜCHI Labortechnik AG with headquarters in Flawil, Switzerland, is a leading provider of laboratory technology solutions for R&D, quality control and production worldwide. Established in 1939, BUCHI serves diverse industries such as pharmaceuticals, chemicals, food & beverage, feed, environmental analysis and academia. BÜCHI Labortechnik GmbH is a fully owned subsidiary of BÜCHI Labortechnik […]
In a new job – December 16, 2024
The company’s Board of Directors has appointed Johan Liwing as the new Chief Executive Officer.
In a new job – December 11, 2024
Oskar Hansson is professor of neurology and research group leader for the clinical memory research unit at Lund University.
In a new job – December 10, 2024
The board has decided to terminate CEO Per Norlén’s employment.
Biotech Business – December 3, 2024
Alligator Bioscience is sharpening its primary focus on its lead asset mitazalimab, and, given current capital restraints, plans to adjust the size of its organization and scope of operations to reflect that.
Biotech Business – November 26, 2024
The rightsizing is expected to result in redundancy of approximately 20 percent of the employees across the CELLINK organization.
Careers article – November 7, 2024
Biotech talent in production is in high demand and Anocca is taking a creative approach to workforce development: investing in motivated young people through in-house training and education.
Profiles in Business – April 23, 2024
Despite being the co-founder of Ilya Pharma and co-director at the Science for Life Laboratory (SciLifeLab), Dr. Mia Phillipson, considers herself a scientist foremost, not an entrepreneur. “Most of all, I am a scientist. Yes, absolutely. This is my main occupation and the one in which I have the most expertise,” says Mia Phillipson, who […]
Business article – April 17, 2024
Personalized medicine, weight loss remedies and new treatments for widespread ailments are among the rising areas of high interest in the biotechnology and therapeutic arenas, according to executive chairman of Flerie Invest, Thomas Eldered. Thomas Eldered talked with Nordic Life Science about the Nordic and global life science financial landscapes and Flerie’s role in funding […]
Business – November 28, 2023
The previous founder and CEO of BioLamina has gone back to business development, and with his newly founded company he aims to redefine cell therapy development even further. Newly founded Alder Therapeutics is a preclinical phase stem cell therapy development company and, according to Kristian Tryggvason, co-founder and CEO, it is “the next big thing.” […]
This site uses cookies
